SHBG Longevity-Medicine Target Ranges: What the Evidence Actually Says

What SHBG Is and Why It Matters for Longevity

SHBG is a glycoprotein produced mainly in the liver that binds testosterone and estradiol with high affinity, leaving only 1 to 3% of testosterone and 2 to 3% of estradiol in the free, biologically active fraction. Aging, body composition, diet, and dozens of medications shift SHBG substantially, making it one of the most clinically important modulators of effective sex-hormone status.

How SHBG Controls Bioavailable Hormone

When SHBG is high, total testosterone or estradiol readings on a standard panel can look normal while the patient has essentially no free hormone reaching tissue receptors. When SHBG is low, total levels may appear adequate while bioavailable concentrations are disproportionately elevated, contributing to androgenic side effects or estrogen-driven tissue effects.

The Endocrine Society's 2010 clinical practice guideline on testosterone therapy states: "Measuring free testosterone by equilibrium dialysis or calculating free testosterone from total testosterone and SHBG is preferable to direct immunoassay methods" when total testosterone is near the lower boundary of the reference range (1). That guidance remains embedded in the 2018 update as well (2).

SHBG as a Longevity Biomarker

Population studies consistently link SHBG to all-cause mortality and cardiometabolic outcomes, independent of total testosterone. A 2019 analysis of 2,913 older men from the European Male Ageing Study (EMAS) found that lower SHBG predicted type 2 diabetes incidence after full adjustment for total testosterone and insulin, with a hazard ratio of 0.72 (95% CI 0.60 to 0.87) per standard deviation increase in SHBG (3). That is, men with higher SHBG were less likely to develop diabetes, even when testosterone was held constant.

At the opposite end, the MrOS Sleep Study of 2,908 older men showed that SHBG above roughly 60 nmol/L was associated with increased fracture risk and frailty markers, partly because very high SHBG correlates with functional androgen deficiency regardless of total T (4).

The Standard Laboratory Reference Range vs. The Longevity-Medicine Target

Reference ranges printed on lab reports are derived from population distributions, not from outcomes data. They define what is statistically common, not what is optimal.

Standard Reference Ranges

Most US clinical laboratories report:

• Men (adults): 10 to 57 nmol/L
• Women (non-pregnant adults): 18 to 144 nmol/L
• Postmenopausal women: 17 to 125 nmol/L (varies by assay)

These numbers shift with age. SHBG rises approximately 1 to 2% per year in men after age 40, meaning a 65-year-old can carry an SHBG of 55 nmol/L that reads "within range" yet have a free testosterone in the hypogonadal zone.

Why the Standard Range Is Too Wide for Clinical Decision-Making

A man with total testosterone of 450 ng/dL and SHBG of 56 nmol/L has a calculated free testosterone near 6.5 pg/mL, which is below the Endocrine Society's suggested lower limit of 9 pg/mL for symptomatic men. That same man's testosterone and SHBG both appear "normal" by population-derived reference ranges.

The NHANES III dataset (N=1,455 men) demonstrated that free testosterone calculated from SHBG correlated far more strongly with lean mass, grip strength, and bone density than total testosterone did (5). Free hormone fraction, not total, predicts tissue-level outcomes.

Longevity-Medicine Consensus Targets

Longevity-focused clinicians, including those applying the American Association of Clinical Endocrinology (AACE) position on individualized hormone optimization, generally converge on the following practical targets:

| Population | Longevity Target | Rationale | |---|---|---| | Men (18 to 50 yrs) | 20 to 45 nmol/L | Preserves free T; below 20 raises metabolic risk signals | | Men (51 to 70 yrs) | 25 to 55 nmol/L | Age-adjusted; above 55 warrants free T calculation | | Men (71+ yrs) | 30 to 60 nmol/L | Rising SHBG with age is expected; functional status guides threshold | | Women, premenopausal | 40 to 120 nmol/L | Supports free estradiol and testosterone balance | | Women, perimenopausal | 35 to 100 nmol/L | Declining ovarian output magnifies SHBG effects | | Women, postmenopausal (no HRT) | 30 to 90 nmol/L | Low SHBG in this group correlates with metabolic syndrome | | Women, postmenopausal (oral estrogen) | 60 to 160 nmol/L | Oral estrogens substantially increase hepatic SHBG output |

These targets are not FDA-approved diagnostic thresholds. They reflect an integration of outcomes literature and clinical experience. A patient's total hormone levels, symptom profile, and metabolic markers must always be interpreted alongside the SHBG value.

What Drives SHBG Up or Down

SHBG is not fixed. A wide range of physiological and pharmacological factors shift it by 30 to 100%, which means the same patient can test very differently depending on when the sample is drawn and what they are taking.

Factors That Lower SHBG

• Obesity and insulin resistance. Hyperinsulinemia directly suppresses hepatic SHBG transcription. Every 1-unit rise in fasting insulin is associated with approximately a 1% fall in SHBG, based on data from the San Antonio Heart Study (6).
• Hypothyroidism. Low free T4 reduces hepatic SHBG synthesis.
• Anabolic androgens. Testosterone, nandrolone, and DHEA all suppress SHBG. Men on intramuscular testosterone cypionate at 100 mg/week typically see SHBG fall 30 to 50% below their pre-treatment baseline.
• Glucocorticoids (excess or exogenous). Cushing's syndrome and chronic prednisone use both reduce SHBG.
• Polycystic ovary syndrome (PCOS). Hyperandrogenism and hyperinsulinemia together can drive SHBG below 30 nmol/L in affected women, amplifying the androgenic signal.
• Progestins (19-nor derivatives). Norethindrone and levonorgestrel have androgenic activity and suppress SHBG more than progesterone.

Factors That Raise SHBG

• Oral estrogens. Oral estradiol or ethinyl estradiol taken by mouth has a first-pass hepatic effect that can double or triple SHBG. Transdermal estradiol has a much smaller effect on SHBG (roughly 10 to 20% increase vs. 100 to 200% with oral routes) (7).
• Hyperthyroidism. Elevated free T4 markedly upregulates SHBG.
• Liver disease (early stages). Hepatitis and cirrhosis show complex, biphasic effects; early hepatic inflammation may raise SHBG.
• Aging. Hepatic production rises gradually with age, independent of testosterone.
• Caloric restriction and low-carbohydrate diets (severe). Prolonged energy deficit can raise SHBG to supraphysiologic levels in some individuals.
• Anticonvulsants. Phenytoin and carbamazepine reliably increase SHBG by 30 to 50%.

SHBG in Men: Clinical Interpretation on TRT

In men receiving testosterone replacement therapy (TRT), SHBG is drawn at the same time as total testosterone, ideally 48 to 72 hours after an injection (trough) or on the day of a weekly dose. Absolute total testosterone means little without knowing SHBG.

When SHBG Is Low on TRT

A man on 100 mg testosterone cypionate per week with a trough total T of 550 ng/dL and SHBG of 14 nmol/L may actually have a free testosterone above 25 pg/mL, which is at the upper end of normal. Erythrocytosis, oily skin, or sleep apnea worsening in this context should prompt dose reduction before assuming more testosterone is needed.

Low SHBG on TRT also tracks poorly with steady-state hormone levels, because when SHBG is very low, testosterone is cleared faster from the circulation, meaning trough values underestimate peak exposure. Some clinicians shift low-SHBG men to more frequent, smaller injections or to transdermal formulations to smooth the peak-to-trough ratio.

When SHBG Is High on TRT

A man on 100 mg/week with total T of 620 ng/dL and SHBG of 62 nmol/L may have a free T near 7 pg/mL, which is hypogonadal by Endocrine Society criteria (2). Dose adjustments in this case should target free testosterone, not total testosterone. Switching to more frequent smaller injections will not fix high SHBG; the underlying driver (hyperthyroidism, anticonvulsants, aging) must be addressed when possible.

A 2018 meta-analysis in JAMA Internal Medicine evaluating testosterone trials in older men found that the symptomatic response to TRT correlated more closely with the change in free testosterone than with the change in total testosterone (8).

SHBG in Women: Clinical Interpretation on HRT and Oral Contraceptives

Women's SHBG is far more sensitive to exogenous hormones than men's, because oral estrogens have a powerful first-pass hepatic effect that raises SHBG by 100 to 300%. This matters enormously for free testosterone and for libido, mood, and energy on hormone therapy.

The Oral Estrogen Problem

Women who switch from oral estradiol (e.g., 1 mg Estrace daily) to transdermal estradiol (e.g., 0.05 mg/day patch) often see SHBG fall 50 to 70%, which raises free testosterone significantly without changing total testosterone at all. Many women report marked libido improvement on transdermal HRT compared to oral HRT, and the SHBG difference is the most plausible mechanistic explanation.

The ESTHER study, a prospective cohort of 881 postmenopausal women, documented that oral estrogen users had 4.2 times the rate of venous thromboembolism compared to transdermal users; SHBG elevation was one of the proposed hepatic markers tracking that risk difference (9).

SHBG and PCOS

Women with PCOS often have SHBG below 30 nmol/L. The Rotterdam Consensus criteria do not include SHBG as a diagnostic criterion, but low SHBG amplifies hyperandrogenism and correlates with the degree of insulin resistance. A 2020 study in the Journal of Clinical Endocrinology and Metabolism (N=2,615 women with PCOS) found that SHBG below 30 nmol/L was the single strongest predictor of metabolic syndrome in the cohort, stronger than either free testosterone or fasting glucose alone (10).

Metformin and myo-inositol both raise SHBG in PCOS by reducing hyperinsulinemia, and the SHBG response to these agents may itself be a useful surrogate for treatment efficacy.

SHBG and Metabolic Disease: The Bidirectional Relationship

Low SHBG is not merely a downstream marker of insulin resistance. There is reasonable evidence that it participates actively in metabolic signaling.

SHBG as a Predictor of Type 2 Diabetes

The largest prospective analysis of SHBG and diabetes risk comes from the Nurses' Health Study. Among 359 incident diabetes cases matched 1:2 to controls, each standard deviation rise in SHBG was associated with a 69% lower risk of type 2 diabetes in women (OR 0.31, 95% CI 0.21 to 0.46, P<0.001) after adjusting for BMI, insulin, and other hormones (11).

In men, a 2011 prospective study in JAMA (N=1,455 men from the MMAS cohort) showed that baseline SHBG independently predicted incident diabetes over 9 years; men in the lowest SHBG quartile had 3.5 times the diabetes incidence of those in the highest quartile (12).

The SHBG Receptor Hypothesis

Research published in Cell Metabolism identified a membrane receptor for SHBG (called RSHBG or megalin/LRP2 in some tissues) on cells including adipocytes and pancreatic beta cells, suggesting SHBG may exert direct intracellular signaling effects independent of its role as a carrier protein (13). This has not yet translated into approved therapeutic targets, but it reframes SHBG from a passive binding protein to a potential active participant in metabolic regulation.

How to Test SHBG Correctly

Getting an accurate, reproducible SHBG result requires attention to pre-analytic variables that many labs do not emphasize.

Pre-Analytic Requirements

• Fasting. SHBG does not change acutely with feeding, but insulin does. Drawing fasting allows free-testosterone calculation and insulin co-interpretation with maximum reliability.
• Morning draw (before 10 a.m.). Testosterone has a diurnal rhythm that is relevant to the calculated free fraction.
• Consistent timing relative to exogenous hormones. For men on testosterone injections, the convention is trough (48 to 72 hours post-injection). For women on cyclic HRT, draw on a consistent day of the cycle.
• Method matters. Immunoassay SHBG is the standard, but some labs use chemiluminescence-based assays with slightly different reference intervals. The same lab and same assay should be used for longitudinal tracking.

Calculated Free Testosterone

Free testosterone by equilibrium dialysis is the gold standard but expensive and rarely available outside academic centers. The Vermeulen formula, which calculates free testosterone from total testosterone, SHBG, and albumin, is endorsed by the Endocrine Society as a clinically acceptable surrogate (1). Most longevity-medicine practices use the online Vermeulen calculator or a built-in LIMS calculation, requiring accurate SHBG and albumin inputs.

Direct Free Testosterone Immunoassay: Avoid It

Direct free testosterone immunoassays available through commercial reference labs (LabCorp, Quest) have consistently poor accuracy and poor reproducibility. The Endocrine Society and AACE both advise against relying on direct free testosterone immunoassay for clinical decisions, particularly in women and in men at the extremes of age (1).

Interventions That Modify SHBG

When SHBG falls outside the longevity target range, clinical management follows the underlying cause, not the SHBG value itself. Treating the cause is always the first step.

Raising Low SHBG

• Reduce hyperinsulinemia. A low-glycemic diet, resistance training, and weight loss of even 5 to 10% body weight can raise SHBG by 10 to 25% in overweight individuals.
• Thyroid optimization. Correcting hypothyroidism reliably raises SHBG toward the middle of the reference range.
• Reduce androgenic progestins. Women on levonorgestrel-containing IUDs or combined oral contraceptives may see SHBG rise substantially on switching to a less androgenic formulation.
• Metformin in insulin-resistant patients. Raises SHBG by 10 to 30% in PCOS and in obese men with low SHBG, primarily via insulin lowering (10).

Lowering High SHBG

Clinically problematic high SHBG is harder to treat pharmacologically without introducing significant risks.

• Address hyperthyroidism first. When thyroid function normalizes, SHBG falls.
• Review and modify medications. Anticonvulsant-driven SHBG elevation may require neurologic collaboration to switch agents.
• Oral DHEA. DHEA at 25 to 50 mg/day modestly lowers SHBG in postmenopausal women in some trials, though evidence is mixed and effect size is small (typically 5 to 15% reduction).
• In men on TRT with persistently high SHBG despite optimization. Some clinicians add a small androgenic agent like oral testosterone undecanoate or increase the TRT dose while targeting free testosterone, but this requires close monitoring of erythrocytosis, prostate-specific antigen, and metabolic parameters.
• Avoid oral estrogens if SHBG is already high. Switching to transdermal estradiol is the most effective single intervention for women with high SHBG on HRT.

The Endocrine Society notes: "The clinical importance of very high SHBG lies in its ability to render total hormone concentrations misleading; treatment decisions should be based on free hormone concentrations in this setting" (2).

SHBG, Bone Density, and Cardiovascular Risk

Beyond metabolic disease, SHBG influences two other domains central to longevity medicine: skeletal integrity and cardiovascular health.

Bone

In the MrOS cohort (N=5,995 older men), SHBG above the median independently predicted lower bone mineral density at the hip (beta coefficient -0.04 g/cm² per SD increase in SHBG, P<0.001) after adjusting for total testosterone, age, and body weight (4). The proposed mechanism is reduced free androgen and free estradiol reaching osteoblasts when SHBG is high.

Cardiovascular

Data here are more complex. Low SHBG associates with obesity, metabolic syndrome, and dyslipidemia, all of which raise cardiovascular risk. A meta-analysis of 11 prospective cohorts (N=11,816 men) published in the European Heart Journal found that men in the lowest SHBG quartile had a 46% higher risk of cardiovascular events compared to those in the highest quartile, after adjustment for conventional risk factors (14). Yet extremely high SHBG, by reducing bioavailable testosterone, may also raise cardiovascular risk through the mechanisms of functional hypogonadism. The sweet spot for cardiovascular longevity in men likely sits between 25 and 55 nmol/L, consistent with the longevity-medicine targets listed above.